ED says Mumbai couple moved 80 kg of mephedrone monthly, raising UAE pharmacy checks

India's Enforcement Directorate (ED) has filed a money-laundering complaint against Faisal Shaikh, Alifya Shaikh and 10 others over an alleged 80 kg monthly mephedrone supply operation in Mumbai, according to The Free Press Journal on 10 October 2026.

The case is outside the UAE, but it matters to Dubai clinics, licensed pharmacies and insurers because FPJ reported an alleged Dubai link in the supply chain. For operators, the immediate question is simple: can every controlled, semi-controlled and psychotropic medicine movement be reconciled by prescriber, patient, batch, date and quantity?

What Indian investigators allege

FPJ reported that the Dongri couple allegedly procured mephedrone from Salim Dola at Rs 7 lakh per kg and sold it at Rs 8 lakh per kg from 2022. The ED has attached properties worth Rs 5.88 crore, and the court had yet to take cognisance of the complaint at the time of FPJ's report.

The reported spread of Rs 1 lakh per kg would imply Rs 80 lakh of monthly gross margin on an alleged 80 kg volume before costs, if the ED's figures are accepted by the court. FPJ also reported that India's Narcotics Control Bureau seized about 15 kg of mephedrone, Rs 1.10 crore in cash, Rs 29.93 lakh from lockers, and about 845 grams of gold jewellery.

FPJ said mephedrone is a banned psychotropic substance under India's Narcotic Drugs and Psychotropic Substances Act. The UAE relevance is the reported overseas coordination. FPJ said Dola was monitoring the operation from Dubai at the relevant time. That allegation has not been tested in a UAE court.

Why Dubai operators should read this as a control test

In Dubai, the relevant regulator is the Dubai Health Authority (DHA). DHA told doctors and pharmacists in 2023 to register for the national platform for prescribing and dispensing narcotic, controlled and semi-controlled medication through its Sheryan circular system. The operational implication is that paper logs, pharmacy system records and platform entries need to match.

For Abu Dhabi and Al Ain, the relevant regulator is the Department of Health Abu Dhabi (DOH). DOH's standard for narcotic, psychotropic and semi-controlled medicinal products applies to healthcare providers, professionals and pharmaceutical facilities licensed by DOH to store, prescribe, dispense, administer or handle those products. The standard defines a drug discrepancy as any mismatch between the physical amount and the recorded amount in the register.

For Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain, operators should read this through the Ministry of Health and Prevention (MOHAP) framework and the services now handled by the Emirates Drug Establishment (EDE). EDE's personal medicine import service says travellers may carry narcotic and psychotropic medicines only within the patient's need for a maximum of three months, with a prescription or medical report. The service completion time is listed as one working day and the fee as AED 0.

• COOs: run a controlled-stock reconciliation for the past 90 days, starting with high-risk medicines and returned stock.
• CFOs: check whether inventory write-offs, cash refunds or manual claim reversals are clustered around controlled medicines.
• CIOs: test whether pharmacy software, e-prescribing records and regulator platform submissions share the same patient and prescription identifiers.
• Medical directors: remind prescribers that controlled medicine documentation has to support diagnosis, dose, duration and patient identity.

What insurers and patients should watch

For insurers such as Daman, Thiqa and Sukoon, the signal is claims behaviour rather than the Indian criminal file. Useful checks include repeat dispensings below approval thresholds, frequent pharmacy switching, early refills and prescriptions issued shortly after international travel. Each flag needs clinical review before a claim is rejected.

Patients need clearer front-desk advice. A patient arriving through Dubai International Airport with an ADHD medicine, pain medicine or sedative may have a lawful prescription but still need to check whether the medicine is controlled in the UAE. The practical route is to search the EDE controlled medicine list, keep the prescription or report, and stay within the three-month personal-use limit.

The legal exposure is material for pharmacies. UAE legislation published in 2025 says a violating pharmacy may face imprisonment of at least five years and a fine of at least AED 50,000 where violations are treated as facilitating narcotic drug use. Operators should seek legal advice before relying on that provision for a specific fact pattern.

For provider selection, patients and payers should use licensed sources rather than social media referrals. Start with the UAE Open Healthcare Directory to find licensed pharmacy providers, then verify controlled-medicine availability and insurance acceptance directly with the pharmacy before travel or treatment.